Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash from Financing Activities (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Cash from Financing Activities for 7 consecutive years, with $421000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 98.75% to $421000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $815000.0 through Dec 2025, down 97.5% year-over-year, with the annual reading at $815000.0 for FY2025, 97.5% down from the prior year.
  • Cash from Financing Activities hit $421000.0 in Q4 2025 for Eton Pharmaceuticals, up from $394000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $33.6 million in Q4 2024 to a low of -$385000.0 in Q1 2022.
  • Historically, Cash from Financing Activities has averaged $1.8 million across 5 years, with a median of -$7000.0 in 2022.
  • Biggest five-year swings in Cash from Financing Activities: crashed 1154.29% in 2023 and later soared 11519.05% in 2024.
  • Year by year, Cash from Financing Activities stood at $68000.0 in 2021, then surged by 45.59% to $99000.0 in 2022, then crashed by 396.97% to -$294000.0 in 2023, then skyrocketed by 11519.05% to $33.6 million in 2024, then crashed by 98.75% to $421000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for ETON at $421000.0 in Q4 2025, $394000.0 in Q1 2025, and $33.6 million in Q4 2024.